The Use of Alefacept in the Treatment of Psoriasis

Skin Therapy Letter-Family Practice Edition

关键词: alefacept;    psoriasis;    immunomodulators Recent evidence clearly demonstrates that psoriasis is mediated by the activation of T-cells;    which opens up a new array of therapeutic approaches to improve the clinical and social impact that it has on affected patients. This knowledge gives us the ability to create molecules that selectively target the steps in the activation of Tlymphocytes. Therefore;    we will be able to treat psoriasis more specifically;    and presumably with fewer side-effects.;   

DOI  :  

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Alefacept (AMEVIVE™ or LFA3TIP, Biogen) is the newest effective systemic therapy for chronic plaque psoriasis and was approved by the US FDA in January 2003. Clinical studies have shown that alefacept, given via weekly IM or IV injections for 12 weeks, was well tolerated, with no reported serious adverse events. Most significantly, it was found that alefacept provides a long-lasting remittive effect. These findings support the use of alefacept as a viable treatment of psoriasis, without the toxicities associated with some of the current systemic treatments available.

【 授权许可】

Unknown